SCHEMBL3605886

SCHEMBL3605886

COc1ncccc1-c1ccnc(N)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.54
CHRNA7 P36544 1/20 0.52
DYRK1A Q13627 4/20 0.49
GSK3B P49841 3/20 0.49
HTR1A P08908 1/20 0.49
HTR7 P34969 1/20 0.49
HTR2B P41595 1/20 0.49
HTR5A P47898 1/20 0.49
NFATC1 O95644 1/20 0.49
CDK5 Q00535 4/20 0.49
CDK5R1 Q15078 4/20 0.49
CCNT1 O60563 2/20 0.49
CCNA2 P20248 2/20 0.49
CDK2 P24941 2/20 0.49
CDK9 P50750 2/20 0.49
CCNA1 P78396 2/20 0.49
PDPK1 O15530 1/20 0.49
HSP90AA1 P07900 2/20 0.46
AURKA O14965 1/20 0.46
PRKACA P17612 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29889747 0.84 GSK3B (0.48) HRH4CHRNA7DYRK1AGSK3BHTR1A
SCHEMBL3613252 0.80 LOXL2 (0.47) HRH4CHRNA7HTR7RAB9ABTK
SCHEMBL503945 0.79 AURKA (0.51) DYRK1AGSK3BCDK5CDK5R1CCNT1
SCHEMBL3362587 0.79 HSP90AA1 (0.60) CHRNA7DYRK1AGSK3BHTR1AHTR7
SCHEMBL30507329 0.79 HSP90AA1 (0.60) CHRNA7DYRK1AGSK3BHTR1AHTR7
SCHEMBL3613255 0.78 TEK (0.51) DYRK1AAURKA
SCHEMBL10915242 0.78 CDK5 (0.53) DYRK1AGSK3BHTR1AHTR7HTR2B
SCHEMBL18013417 0.77 CCNT1 (0.49) DYRK1AGSK3BHTR1AHTR7HTR2B
SCHEMBL21908934 0.77 CDK5 (0.41) DYRK1AGSK3BHTR1AHTR7HTR2B
SCHEMBL27944087 0.76 DHFR (0.56) HRH4CHRNA7BTKALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed
WO-2008079933-A2 HETEROARYL-HETEROARYL COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER, INFLAMMATION AND VIRAL INFECTIONS NOVARTIS AG (CH) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048597-A1 Organic Compounds and Their Uses OAT, OTC, AOX1 HRH4 2383/4885CHRNA7 2978/4885DYRK1A 4791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.